Hematological toxicities associated with amphotericin B formulations.

abstract：:The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

journal_title：Leukemia & lymphoma

authors： Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

更新日期：2015-01-01 00:00:00

abstract：:In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

journal_title：Leukemia & lymphoma

authors： Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

更新日期：2012-01-01 00:00:00

abstract：:To evaluate the prognostic features of Ph+ CML patients treated by allogeneic BMT or by IFN, we reviewed the data of 50 consecutive pts who were transplanted between 1984 and 1988 and of 180 consecutive patients who were assigned to continuous IFN treatment between 1986 and 1988. In the BMT group, Sokal's system predi...

journal_title：Leukemia & lymphoma

authors：

更新日期：1993-01-01 00:00:00

abstract：:Natural killer (NK) cells provide anti-infectious, anti-neoplastic, and immunomodulatory function effected by both cytokine production and direct cellular cytotoxicity that is not major histocompatibility complex-restricted. NK cells lack truly specific cell surface determinants as well as antigen-specific receptors. ...

journal_title：Leukemia & lymphoma

authors： Morice WG,Leibson PJ,Tefferi A

更新日期：2001-04-01 00:00:00

abstract：:CD30 ligand (CD30L) is a type-II membrane glycoprotein capable of transducing signals through its specific counterstructure CD30. Even though there are indications that CD30L plays a key role as a paracrine-acting surface molecule in the deregulated cytokine cascade of Hodgkin's disease, little is known about its biol...

journal_title：Leukemia & lymphoma

authors： Gattei V,Degan M,Rossi FM,de Iuliis A,Mazzocco FT,Serraino D,Zagonel V,Aldinucci D,Pinto A

更新日期：1999-09-01 00:00:00

abstract：:Bryostatin, a macrocyclic lactone and protein kinase C (PKC) modulator, has been shown to have differentiation and anti-tumor activity against several leukemia cell lines in vitro. In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by a...

journal_title：Leukemia & lymphoma

authors： Thomas A,Pepper C,Hoy T,Bentley P

更新日期：2004-05-01 00:00:00

abstract：:There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

journal_title：Leukemia & lymphoma

authors： Schultze JL

更新日期：1999-01-01 00:00:00

abstract：:This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

journal_title：Leukemia & lymphoma

authors： Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

更新日期：2018-08-01 00:00:00

abstract：:Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...

journal_title：Leukemia & lymphoma

authors： Nokes TJ,Johnson S,Harvey D,Goldstone AH

更新日期：1997-09-01 00:00:00

abstract：:The blast cells from up to 70% of patients with acute myeloblastic leukaemia exhibit a variable degree of autonomous growth in vitro, which is related to the production of autocrine growth factors. It has recently been established that patients with autonomous blast cell growth have both a lower remission rate and a h...

journal_title：Leukemia & lymphoma

authors： Russell NH,Hunter AE,Bradbury D,Zhu YM,Keith F

更新日期：1995-01-01 00:00:00

abstract：:Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This...

journal_title：Leukemia & lymphoma

authors： Brown JR

更新日期：2014-02-01 00:00:00

abstract：:B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

journal_title：Leukemia & lymphoma

authors： Wang P,Pavletic ZS,Joshi SS

更新日期：2002-09-01 00:00:00

abstract：:The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...

journal_title：Leukemia & lymphoma

authors： Reinke EN,Bera S,Diamond AM

更新日期：2015-04-01 00:00:00

abstract：:Endoglin (CD105) is a component of the transforming growth factor-beta (TGF-beta) receptor (TGF-betaR) complex. Together with betaglycan, CD105 is considered as a TGF-betaR accessory molecule (also called TGF-betaRIII), but its functions in the receptor-ligand interactions are still poorly understood. A small subset o...

journal_title：Leukemia & lymphoma

authors： Pierelli L,Bonanno G,Rutella S,Marone M,Scambia G,Leone G

更新日期：2001-11-01 00:00:00

abstract：:This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine (2CdA) in whom severe depletion of T lymphocyte subsets was observed. Four patients enrolled into the study had previously been treated with 3-6 courses of 2Cd...

journal_title：Leukemia & lymphoma

authors： Dmoszyńska A,Legiec W,Wach M

更新日期：1999-07-01 00:00:00

abstract：:The risk for opportunistic infections is correlated with low CD4+ T lymphocyte counts in patients with HIV. We performed a retrospective analysis in 54 patients with multiple myeloma undergoing high-dose melphalan chemotherapy + autologous peripheral blood stem cell transplantation to better define the value of routin...

journal_title：Leukemia & lymphoma

authors： Gorschlüter M,Glasmacher A,Sarazin S,Hackbarth F,Hoebert E,Orlopp K,Schmidt-Wolf IG,Mey U

更新日期：2007-03-01 00:00:00

abstract：:The rearrangement of the immunoglobulin genes (IG) provides a large diversity of B-cell receptors conformations and allows the immune system to respond differently to foreign antigens. In chronic lymphocytic leukemia (CLL), there are a restricted number of stereotyped B-cell receptors rearranged by the tumor B-cells b...

journal_title：Leukemia & lymphoma

authors： Tobin G

更新日期：2007-06-01 00:00:00

abstract：:Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma that presents with symptomatic anemia, thrombocytopenia, constitutional symptoms, extramedullary disease and rarely hyperviscosity syndrome. The presence of both IgM monoclonal protein and ≥10% monoclonal lymphoplasmacytic cells is required for the dia...

journal_title：Leukemia & lymphoma

authors： Vaxman I,Gertz M

更新日期：2020-06-01 00:00:00

abstract：:Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with p-values <.05 in logrank analysis were included as pa...

journal_title：Leukemia & lymphoma

authors： Lentz R,Feinglass J,Ma S,Akhter N

更新日期：2019-06-01 00:00:00

abstract：:Isolated central nervous system (CNS) relapse was evaluated in terms of incidence, risk factors, and outcome in a consecutive cohort of 175 patients with aggressive non-Hodgkin's lymphoma in which no case of lymphoblastic or Burkitt's lymphoma was encountered. All these patients had obtained a complete remission with ...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Magagnoli M,Frezza G,Prologo G,Gherlinzoni F,Bendandi M,Albertini P,Babini L,D'Alessandro R,Tura S

更新日期：1999-02-01 00:00:00

abstract：:Abstract Reconstitution, engraftment kinetics and tumor cell clearance were analyzed after reduced intensity conditioning hematopoietic cell transplant (RIC-HCT) in patients with chronic lymphocytic leukemia (CLL). Patients were transplanted from unrelated (n = 40) or related (n = 10) donors after fludarabine and 2 Gy...

journal_title：Leukemia & lymphoma

authors： Hebenstreit K,Iacobelli S,Leiblein S,Eisfeld AK,Pfrepper C,Heyn S,Vucinic V,Franke GN,Krahl R,Fricke S,Becker C,Pönisch W,Behre G,Niederwieser D,Lange T

更新日期：2014-06-01 00:00:00

abstract：:The MTT-based assay relies upon the cellular reduction of tetrazolium salts to their intensely colored formazans. The test is easy to perform in hematological malignancies and is adaptable for high throughput of samples, although there are some minor limitations in its application resulting from metabolic interference...

journal_title：Leukemia & lymphoma

authors： Hayon T,Dvilansky A,Shpilberg O,Nathan I

更新日期：2003-11-01 00:00:00

abstract：:Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we document...

journal_title：Leukemia & lymphoma

authors： Osuji N,Del Giudice I,Matutes E,Morilla A,Owusu-Ankomah K,Morilla R,Dunlop A,Catovksy D

更新日期：2005-05-01 00:00:00

abstract：:Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containin...

journal_title：Leukemia & lymphoma

authors： Carella AM,de Souza CA,Luminari S,Marcheselli L,Chiappella A,di Rocco A,Cesaretti M,Rossi A,Rigacci L,Gaidano G,Merli F,Spina M,Stelitano C,Hohaus S,Barbui A,Puccini B,Miranda EC,Guida A,Federico M

更新日期：2013-01-01 00:00:00

abstract：:Although considered the same disease by 2016 WHO Classification, B-ALL and B-LBL show different clinicobiologic behavior, with B-ALL manifesting as disseminated disease and B-LBL as a localized mass. Distinction between the two is based on an arbitrary cutoff of 25% bone marrow involvement. We reviewed clinical, immun...

journal_title：Leukemia & lymphoma

authors： Knez V,Bao L,Carstens B,Liang X

更新日期：2020-09-01 00:00:00

abstract：:Multiple myeloma represents a B cell malignancy characterized by a monoclonal proliferation of plasma cells. A striking feature of the disease is the tendency of the malignant plasma cells to affect mainly the bone marrow environment and to invade the peripheral blood only in the terminal stage. The growth of myeloma ...

journal_title：Leukemia & lymphoma

authors： Van Riet I,Van Camp B

更新日期：1993-04-01 00:00:00

abstract：:A review of recent information on the expression and the ATRA-driven modulation of cell surface adhesion molecules of acute myelogenous leukemia blast cells is presented. Cytofluorometric studies on fresh blast cells have demonstrated that CD11a, CD11b CD11c, CD15, CD45RO and CD54 expression is significantly lower in ...

journal_title：Leukemia & lymphoma

authors： Di Noto R,Lo Pardo C,Schiavone EM,Ferrara F,Manzo C,Vacca C,Del Vecchio L

更新日期：1996-04-01 00:00:00

abstract：:Multiple myeloma typically presents with monoclonal proteinemia, marrow plasmacytosis, anemia, bony involvement, hypercalcemia and renal insufficiency. Less frequent presentations include hepatic and splenic enlargement (5% of cases), lymphadenopathy (4%) and biclonal gammopathy (1%). Chemotherapy may produce remissio...

journal_title：Leukemia & lymphoma

authors： Daeninck PJ,Williams GJ,Rubinger M,Johnston JB

更新日期：1997-12-01 00:00:00

abstract：:Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...

journal_title：Leukemia & lymphoma

authors： Jillella AP,Day DS,Severson K,Kallab AM,Burgess R

更新日期：2000-07-01 00:00:00

abstract：:Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking t(8;21) may occasionally express CD19. We asked whether CD19 expression is restricted to the karyotypically abnormal leukemic cells in primary leukemia sa...

journal_title：Leukemia & lymphoma

authors： Francis J,Dharmadhikari AV,Sait SN,Deeb G,Wallace PK,Thompson JE,Wang ES,Wetzler M

更新日期：2013-07-01 00:00:00